6月9日 - ** 生物技术公司Cartesian Therapeutics（RNAC.O）的股价在盘前交易中上涨8.4%，至6.35美元
** 该公司表示已与中国西基因生物医药（WestGene Biopharma）签署许可协议，共同开发用于治疗自身免疫性疾病的体内CAR-T疗法，此类疾病中免疫系统会攻击健康组织
** 称该疗法结合了其mRNA技术与西基因的脂质纳米颗粒（LNP）递送系统，旨在靶向体内的免疫细胞
** 称针对罕见神经肌肉疾病重症肌无力的临床试验将于2026年下半年启动；预计2027年上半年公布数据
** 补充称该方案可支持重复给药，并避免体外复杂的细胞制备过程
** 公司表示，此次合作还扩展了针对与自身免疫性疾病相关的BCMA蛋白的研发管线
** 截至上一交易日收盘，该公司股价年内累计下跌约19%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.